Late-clinical stage biotechnology company Nanobiotix (Euronext Paris:NANO) (NASDAQ:NBTX) announced on Tuesday that the first patient has been dosed in the CONVERGE study, a Phase 2 trial evaluating JNJ-1900 (NBTXR3), a radioenhancer, for Stage 3 unresectable non-small cell lung cancer.

The study is sponsored by Janssen Pharmaceutica NV, a Johnson & Johnson (NYSE:JNJ) Company, under a global licence agreement.

NBTXR3 is a novel nanoparticle-based therapy designed to enhance the effects of radiotherapy on tumours. It is also under evaluation in other solid tumours, including a Phase 3 trial in head and neck cancer.

Nanobiotix has a strategic focus on expanding NBTXR3 development through collaborations with academic institutions and pharmaceutical companies.

This collaboration with Janssen marks a significant step in advancing the potential of NBTXR3 for patients with lung cancer.